Hilton Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-3,295
Closed -$446K 152
2021
Q2
$446K Hold
3,295
0.05% 76
2021
Q1
$447K Hold
3,295
0.05% 66
2020
Q4
$464K Buy
+3,295
New +$422K 0.05% 61

Other funds holding XBI

Hilton Capital Management's XBI Position: Q3 2021 in Review

Hilton Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2021, closing a stake of 3,295 shares — an estimated $446K sold.

Hilton Capital Management first reported a position in XBI in Q4 2020 and held it in 3 quarters. The position peaked at $464K in Q4 2020. 635 funds tracked by Wall St. Rank hold XBI as of Q3 2021.

  • Hilton Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2021 after selling out during the quarter.
  • Hilton Capital Management sold 3,295 State Street SPDR S&P Biotech ETF shares in Q3 2021, an estimated $446K.
  • Hilton Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 3 quarters.
  • Hilton Capital Management's State Street SPDR S&P Biotech ETF position peaked at $464K in Q4 2020.
  • 635 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2021.

Based on Hilton Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.